GSK (GSK) to support manufacture of Novavax' (NVAX) COVID-19 vaccine
- Wall St rallies on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
UPDATE: Glaxo (GSK) to Manufacture Novavax (NVAX) Covid Shot Securing U.K. Suppy - Bloomberg
March 29, 2021 12:01 PM EDT(Updated - March 29, 2021 12:04 PM EDT)
GlaxoSmithKline (NYSE: GSK) is set to manufacture as many as 60 million U.K. doses of a Covid-19 vaccine from Novavax (NASDAQ: NVAX), according to Bloomberg, citing a statement from Glaxo.
... More